What is the 13F Pro Quality Score for OBIO?

13F Pro ranks Orchestra BioMed Holdings, Inc. (OBIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OBIO's current score at https://13fpro.ai/research/OBIO (free sign-up required for the full ranking).

Where does 13F Pro source OBIO data?

All Orchestra BioMed Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Orchestra BioMed Holdings, Inc. files with the SEC under CIK 1814114. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OBIO in?

Orchestra BioMed Holdings, Inc. (OBIO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OBIO research updated on 13F Pro?

OBIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Orchestra BioMed Holdings, Inc.(OBIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1814114 OBIO stock profile & AI dashboard →

13F Pro Quality Score

8.7/100

Rank #2,823 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

15.5/100

Profitability

1.1/100

Balance Sheet

1.8/100

Earnings Quality

30.0/100

Free Cash Flow

1.1/100

Institutional Flow

58.9/100

Revenue Scale

1.2/100

Dilution Risk

5.6/100

OBIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Orchestra BioMed Holdings, Inc. (OBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OBIO at 8.7/100 on a 32-signal composite quality model, placing it at rank #2,823 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (1.1) and free cash flow (1.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Orchestra BioMed Holdings, Inc. reports quarterly revenue of $110.0K, net income of $-20.7M, free cash flow of $-22.4M. Top institutional holders of OBIO by reported 13-F value include RTW INVESTMENTS,, PERCEPTIVE ADVISORS, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. OBIO trades on the Nasdaq exchange and files with the SEC under CIK 1814114. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Orchestra BioMed Holdings, Inc. directly from SEC EDGAR. Orchestra BioMed Holdings, Inc.'s 13F Pro composite quality score has ranged between 9 and 17 since 2026, currently 8.7 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Orchestra BioMed Holdings, Inc.

Quirks, history, and lore behind OBIO — the kind of stuff that makes a stock memorable.

1
The Basics
A medical device company in the healthcare sector · listed on Nasdaq · headquartered in Pennsylvania.
2
The Numbers
A small-cap clinical-stage company with limited revenue and a balance sheet fueled primarily by equity financing — the kind where every quarterly report is more about pipeline than profit.
3
The History
Founded with a mission to reinvent how chronic cardiovascular disease is treated, using bioelectronic medicine to stimulate the body's own nervous system rather than drugs or traditional devices.
4
The Secret
Its lead technology targets hypertension and heart failure by delivering mild electrical pulses to baroreceptors — pressure sensors your body already owns but rarely gets to use therapeutically.
5
The Lore
The company operates under a novel co-development model, partnering with larger medtech strategics to share risk and resources — think of it as a startup with a big-company safety net.
6
The Giveaway
Its name blends orchestrated biology with biomedical ambition, and its flagship device — the Moderato System — is designed to literally tune your heart like an instrument.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$110.0K

Net Income

Q1 2026

$-20.7M

Free Cash Flow

Q1 2026

$-22.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1169.2% YoY

$33.5MFY 2025

FY21 —FY24 $2.6MFY25 $33.5M

Net Income

+13.6% YoY

$-52.7MFY 2025

FY21 $-378.8KFY24 $-61.0MFY25 $-52.7M

Operating Income

+19.4% YoY

$-51.8MFY 2025

FY21 $-394.8KFY24 $-64.3MFY25 $-51.8M

EPS (Diluted)

+33.1% YoY

$-1.11FY 2025

FY21 $-0.02FY24 $-1.66FY25 $-1.11

Total Assets

+50.8% YoY

$114.9MFY 2025

FY21 $161.8MFY24 $76.2MFY25 $114.9M

Total Debt

+0.0% YoY

$15.0MFY 2025

FY21 —FY24 $15.0MFY25 $15.0M

Op. Cash Flow

+3.2% YoY

$-49.0MFY 2025

FY21 $-272.4KFY24 $-50.6MFY25 $-49.0M

Metric	FY 2025	FY 2024	FY 2021
Revenue	$33.5M +1169.2%	$2.6M	—
Net Income	$-52.7M +13.6%	$-61.0M -16011.8%	$-378.8K
Operating Income	$-51.8M +19.4%	$-64.3M -16188.8%	$-394.8K
EPS (Diluted)	$-1.11 +33.1%	$-1.66 -8200.0%	$-0.02
Total Assets	$114.9M +50.8%	$76.2M -52.9%	$161.8M
Total Debt	$15.0M +0.0%	$15.0M	—
Operating Cash Flow	$-49.0M +3.2%	$-50.6M -18462.8%	$-272.4K

AI Insight: OBIO Ratio Trends

Orchestra swung to profitability in Q4 2025, but TTM metrics remain deeply negative as Q1 2026 reverts to losses.

• Q4 2025 delivered 21.9% operating margin and 20.2% net profit margin, first profitable quarter in dataset.

• ROA deteriorated sharply in Q1 2026 to -82.2%, reversing Q4 2025's positive 21.8% ROA.

• TTM operating margin of -168.0% and NPM of -167.0% indicate cumulative losses dwarf Q4 2025 gains.

⚠ Q1 2026 loss reversal suggests Q4 2025 profit may be seasonal or one-time; sustainability in doubt.

⚠ Extreme metric gaps: Q1 2025–Q2 2025 data missing entirely; monitor reporting consistency.

Get alerted when OBIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Orchestra BioMed Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OBIO

RTW INVESTMENTS, LP
$35.3M8,306,063 sh
PERCEPTIVE ADVISORS LLC
$21.4M5,037,906 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.4M2,204,319 sh
Alyeska Investment Group, L.P.
$4.3M1,000,000 sh
Propel Bio Management, LLC
$3.8M896,701 sh
MILLENNIUM MANAGEMENT LLC
$3.0M702,543 sh
BlackRock, Inc.
$2.7M635,714 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.1M485,492 sh
Affinity Asset Advisors, LLC
$1.7M402,550 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$1.1M265,499 sh

Fund	Value	Shares
RTW INVESTMENTS, LP	$35.3M	8,306,063
PERCEPTIVE ADVISORS LLC	$21.4M	5,037,906
VANGUARD CAPITAL MANAGEMENT LLC	$9.4M	2,204,319
Alyeska Investment Group, L.P.	$4.3M	1,000,000
Propel Bio Management, LLC	$3.8M	896,701
MILLENNIUM MANAGEMENT LLC	$3.0M	702,543
BlackRock, Inc.	$2.7M	635,714
GEODE CAPITAL MANAGEMENT, LLC	$2.1M	485,492
Affinity Asset Advisors, LLC	$1.7M	402,550
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$1.1M	265,499

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OBIO on your watchlist

Track score changes the day Orchestra BioMed Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OBIO a good stock to buy?

13F Pro's AI-powered analysis of Orchestra BioMed Holdings, Inc. (OBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OBIO are available on the OBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OBIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Orchestra BioMed Holdings, Inc.'s investment landscape.